Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936910 · ClinicalTrials.gov registry record · Phase 4
Antifungal Locks to Treat Fungal-related Central Line Infections
A Phase 4 study of Central Line Fungal Infections, sponsored by Bill McGhee.
- Completed
- Registry status
- Phase 4
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT00936910 is a Phase 4 study of Central Line Fungal Infections that has completed, run by Bill McGhee. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00936910, a Phase 4 study of Central Line Fungal Infections, has completed, sponsored by Bill McGhee.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the usefulness of antifungal lock therapy with liposomal amphotericin B (Ambisome), in combination with systemic antifungal(s), in patients with catheter-related blood stream infections with fungal organisms, whose catheter has not been removed because of the continuing critical need for central line access. The primary group of potential patients will be those with intestinal insufficiency, including post-op small bowel transplant recipients. The recommendation of the Infectious Disease Society of America (IDSA) is to remove all catheters with fungal infections and treat systemically for 14 days after the last positive culture. However, in certain intestinal failure patients, removal of an infected line might significantly reduce or eliminate intravenous (IV) access and create a life threatening situation. Thus, the investigators' aim is to determine the usefulness of antifungal lock therapy in intestinal failure patients whose catheter has not been removed. The investigators' hope is to salvage central line catheters rather than to remove them.
Conditions Studied
Interventions
- DRUG amphotericin B liposomal (Ambisome)
Study Locations (1)
Pennsylvania
- Children's Hospital of Pittsburgh - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-09 |
| Est. Completion | 2010-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936910
The ClinicalTrials.gov registry entry for NCT00936910 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bill McGhee, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Central Line Fungal Infections appearing as the primary indexed condition, and to 1 intervention - of which amphotericin B liposomal (Ambisome) is the first listed.
NCT00936910 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00936910 about?
NCT00936910 is a clinical study titled "Antifungal Locks to Treat Fungal-related Central Line Infections". The purpose of this study is to evaluate the usefulness of antifungal lock therapy with liposomal amphotericin B (Ambisome), in combination with systemic antifungal(s), in patients with catheter-related blood stream infections with fungal organisms, whose catheter has not been removed because of the...
What is the current status of trial NCT00936910?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 13 participants. The study started on 2006-09. Estimated completion is 2010-09.
What conditions does trial NCT00936910 study?
This clinical trial studies the following conditions: Central Line Fungal Infections.
What interventions are being tested in trial NCT00936910?
The interventions under investigation include: amphotericin B liposomal (Ambisome) (DRUG).
Who is sponsoring clinical trial NCT00936910?
This trial is sponsored by Bill McGhee, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00936910 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.